The Role of Circulating Biomarkers in the Early Diagnosis of Ovarian Cancer

Gumusoglu‐Acar, Ece; Günel, Tuba

doi:10.5772/intechopen.75484

Cited by 12 publications

(13 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Firstly, patients usually are asymptomatic or present with vague non-specific symptoms at early stages [12]. Secondly, the unavailability of minimally invasive screening procedures, leading patients to undergo invasive surgical biopsies to be correctly diagnosed and stagged [13].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Elevated Interleukin-6 Levels in the Circulation and Peritoneal Fluid of Patients with Ovarian Cancer as a Potential Diagnostic Biomarker: A Systematic Review and Meta-Analysis

Amer¹,

Kartikasari²,

Plebanski³

2021

JPM

View full text Add to dashboard Cite

Ovarian cancer (OC) is one of the most lethal cancers, largely due to a late diagnosis. This study aimed to provide a comprehensive meta-analysis on the diagnostic performance of IL6 in the blood and ascites separately for advanced and early-stage OC. We included 37 studies with 6948 participants detecting serum or plasma IL6. The plasma/serum IL6 mean level in the late-stage OC was 23.88 pg/mL (95% CI: 13.84–41.23), and the early-stage OC was 16.67 pg/mL (95% CI: 510.06–27.61), significantly higher than the healthy controls at 3.96 pg/mL (95% CI: 2.02–7.73), but not significantly higher than those found in the controls with benign growths in the ovary, which was 9.63 pg/mL (95% CI: 4.16–22.26). To evaluate IL6 in ascites as a diagnostic marker, we included 26 studies with 1590 participants. The mean level of ascitic IL6 in the late-stage OC was 3676.93 pg/mL (95% CI: 1891.7–7146.7), and the early-stage OC was 1519.21 pg/mL (95% CI: 604.6–3817.7), significantly higher than the benign controls at 247.33 pg/mL (95% CI: 96.2–636.0). There was no significant correlation between the levels of circulating and ascitic IL6. When pooling all OC stages for analysis, we found that serum/plasma IL6 provided 76.7% sensitivity (95% CI: 0.71–0.92) and 72% specificity (95% CI: 0.64–0.79). Ascitic IL6 provided higher sensitivity at 84% (95% CI: 0.710–0.919) and specificity at 74% (95% CI: 0.646–0.826). This study highlights the utility of ascitic IL6 for early detection of OC.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Cancer-specific biomarkers circulating in the blood can be utilized in minimally invasive diagnostic procedures to detect the presence of cancers [13]. In OC, although not specific, Carcinogen Antigen 125 (CA125) and Human Epididymis 4 (HE4) are approved circulating biomarkers used at clinics for OC monitoring and follow-ups [14].…”

Section: Introductionmentioning

confidence: 99%

Elevated Interleukin-6 Levels in the Circulation and Peritoneal Fluid of Patients with Ovarian Cancer as a Potential Diagnostic Biomarker: A Systematic Review and Meta-Analysis

Amer¹,

Kartikasari²,

Plebanski³

2021

JPM

View full text Add to dashboard Cite

show abstract

“…This could be explained as lncRNAs exert “sponge‐like” effects on various miRNAs, which subsequently inhibits miRNA‐mediated functions and downstream targets; PELI3 expression in this study based on bioinformatic analysis. Thus, crosstalk between two ncRNAs could contributes to the disease pathogenesis including cancer …”

Section: Discussionmentioning

confidence: 99%

Role of a novel circulatory RNA‐based biomarker panel expression in ovarian cancer

et al. 2019

View full text Add to dashboard Cite

Ovarian cancer (OC) is considered the sixth commonest cancer affecting women globally. We choose novel integrated specific ovarian cancer RNA biomarker panel; pellino E3 ubiquitin protein ligase family member 3 (PELI3) gene expressions along with its selected epigenetic regulators (microRNA (miR-361-3p) and long noncoding RNA (lncRNA RP5-837J1.2) by bioinformatic methods. Then, differential expressions of the selected panel in the sera of 50 OC patients, 42 cases with benign ovarian lesions, and among 45 controls were determined using realtime polymerase chain reaction quantitative (qRT-PCR). Furthermore, their expression was measured also in malignant ovarian tissues and adjacent nontumor tissues in 23 of 50 OC patients by quantitative qRT-PCR. The current study reported, for the first time, upregulation of serum lncRNA RP5-837J1.2 with concomitant downregulation of miR-361-3p and PELI3 mRNA in malignant group compared with benign and controls groups. There were associations of serum lncRNA RP5-837J1.2 with the affected ovary and worse International Federation of Gynecology and Obstetrics staging; associations of miR-361-3p with tumor size, grade, stage, and presence of metastasis; as well as associations among PELI3 mRNA expression and tumor size, grade, stage, and presence of metastasis among the OC group. In tumor tissues, miR-361-3p and PELI3 mRNA levels were at a higher level than that of nontumor tissues; however, tumor tissue showed lower level of lncRNA RP5-837J1.2 compared to normal tissue. There were positive correlations between serum and tissue level of RNA RP5-837J1.2, miR-361-3p, and PELI3 mRNA, but they did not reach statistical significance. Receiver operating characteristics curve analyses showed that lncRNA RP5-837J1.2, miR-361-3p, and PELI3 mRNA expression levels can discriminate among OC patient, cases with benign Abbreviations: AUC, Area under the curve; BMI, body mass index; CA125, cancer antigen 125; CEA, carcinoembryonic antigen; FIGO, International Federation of Gynecology and Obstetrics; IRAK1, interleukin-1 receptor-associated kinase 1; lncRNA, long noncoding RNA; NSCLC, non-small cell lung cancer; OC, Ovarian cancer; PELI3, Pellino E3 ubiquitin protein ligase family member 3; qRTPCR, polymerase chain reaction; ROC, receiver operating characteristic; RQ, relative quantity; TLRs, Toll-like receptors; TNF, tumor necrosis factor; TRAF6, TNF receptor-associated factor 6 complex.

show abstract

“…For the specific determination of an oncomarker, it must possess a few characteristic traits. The characteristics of an ideal biomarker are as follows: ,, (i) it should have high sensitivity and specificity to only one type of tumor, (ii) it must be acceptable to patients undergoing the test, (iii) predictive and prognostic benefits of tumor biomarker must have both positive and negative predictive values, and (iv) a prospective trial must verify their clinical value. Unfortunately, such an ideal biomarker does not currently exist.…”

Section: Biomarkers For Ovarian Carcinomamentioning

confidence: 99%

Biomarkers for Early Diagnosis of Ovarian Carcinoma

Manasa¹,

Mascarenhas²,

Shetti

et al. 2022

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

The leading cause of gynecological cancer-related morbidity and mortality is ovarian cancer (OC), which is dubbed a silent killer. Currently, OC is a target of intense biomarker research, because it is often not discovered until the disease is advanced. The goal of OC research is to develop effective tests using biomarkers that can detect the disease at the earliest stages, which would eventually decrease the mortality, thereby preventing recurrence. Therefore, there is a pressing need to revisit the existing biomarkers to recognize the potential biomarkers that can lead to efficient predictors for the OC diagnosis. This Perspective covers an update on the currently available biomarkers used in the triaging of OC to gain certain insights into the potential role of these biomarkers and their estimation that are crucial to the understanding of neoplasm progression, diagnostics, and therapy.

show abstract

The Role of Circulating Biomarkers in the Early Diagnosis of Ovarian Cancer

Cited by 12 publications

References 84 publications

Elevated Interleukin-6 Levels in the Circulation and Peritoneal Fluid of Patients with Ovarian Cancer as a Potential Diagnostic Biomarker: A Systematic Review and Meta-Analysis

Elevated Interleukin-6 Levels in the Circulation and Peritoneal Fluid of Patients with Ovarian Cancer as a Potential Diagnostic Biomarker: A Systematic Review and Meta-Analysis

Role of a novel circulatory RNA‐based biomarker panel expression in ovarian cancer

Biomarkers for Early Diagnosis of Ovarian Carcinoma

Contact Info

Product

Resources

About